{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:25:14Z","timestamp":1741238714125,"version":"3.38.0"},"reference-count":28,"publisher":"JLE","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.nephro.2017.01.004","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T06:16:19Z","timestamp":1496297779000},"page":"S103-S108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Oxyhydroxyde sucroferrique, un nouveau ch\u00e9lateur des phosphates \u00e0 base de fer. Quelle utilisation chez le patient dialys\u00e9\u00a0?"],"prefix":"10.1684","volume":"13","author":[{"given":"Pierre","family":"Bataille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Delattre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mait\u00e9","family":"Daroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2017.01.004_bib0145","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2215\/CJN.11901115","article-title":"Phosphate toxicity in CKD: the killer among us","volume":"11","author":"Ritter","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0150","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"113\u00a0Suppl","author":"Kidney Disease: improving global outcomes (KDIGO) CKB-MBD Work Group","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.01.004_bib0155","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3945\/ajcn.2008.26665","article-title":"Is contolling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?","volume":"88","author":"Shinaberger","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.nephro.2017.01.004_bib0160","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","article-title":"Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis","volume":"382","author":"Jamal","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2017.01.004_bib0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/CN108119","article-title":"The iron-based phosphate binder PA21\u00a0has a potent phosphate binding capacity and minimum iron release across a physiological ph range in vitro","volume":"81","author":"Wilhelm","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0170","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1523-1755.2004.09005.x","article-title":"A comparison of clinically useful phosphorus binders for patients with chronic kidney failure","volume":"66\u00a0Suppl.","author":"Emmett","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.01.004_bib0175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.5414\/CNP64320","article-title":"Gastric pH, sevelamer hydrochloride and omeprazole","volume":"64","author":"Capitanini","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0180","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5414\/CNP74004","article-title":"PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease","volume":"74","author":"Geisser","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0185","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21\u00a0in hemodialysed patients","volume":"8","author":"W\u00fcthrich","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0190","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A Phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.01.004_bib0195","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.004_bib0200","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfw242","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","author":"Covic","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.004_bib0205","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000447600","article-title":"Pharmacodynamic effects of sucroferric oxyhydroxyde and sevelamer carbonate on vitamin D receptor agonist bioactivity in dialysis patients","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0210","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ndt\/gfq598","article-title":"The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol","volume":"26","author":"Pierce","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.004_bib0215","first-page":"755A","article-title":"Analysis of CKD-MBD markers in a phase 3\u00a0study of PA21\u00a0and sevelamer in patients with hyperphosphatemia","volume":"24","author":"Sprague","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0220","series-title":"Cape-Town: International Congress of Nephrology","article-title":"CKD-MBD markers in a phase 3\u00a0study of sucroferric oxyhydroxide in dialysis patients with hyperphosphatemia","author":"Ketteler","year":"2015"},{"key":"10.1016\/j.nephro.2017.01.004_bib0225","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CN107764","article-title":"The effect of phosphate binders, calcium and lanthanum carbonate on FGF23\u00a0levels in chronic kidney disease","volume":"80","author":"Soriano","year":"2013","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0230","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/ndt\/gft234","article-title":"Disturbances of Wnt\/\u03b2-catenin pathway and energy metabolism in early CKD: effect of phosphate binders","volume":"28","author":"De Oliveira","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.004_bib0235","doi-asserted-by":"crossref","first-page":"515606","DOI":"10.1155\/2015\/515606","article-title":"Effects of sucroferric oxyhydroxide compared to lanthanum carbonate and sevelamer carbonate on phosphate homeostasis and vascular calcifications in a rat model of chronic kidney failure","volume":"2015","author":"Phan","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.nephro.2017.01.004_bib0240","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40620-014-0080-1","article-title":"Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects","volume":"27","author":"Chong","year":"2014","journal-title":"J Nephrol"},{"year":"2013","series-title":"Post-hoc analysis of pharmacodynamic interaction of PA21\u00a0with statins in a phase 3\u00a0study of PA21\u00a0in dialysis patients with hyperphosphatemia","author":"Levesque","key":"10.1016\/j.nephro.2017.01.004_bib0245"},{"key":"10.1016\/j.nephro.2017.01.004_bib0250","first-page":"462A","article-title":"Pill number and serum phosphorus in hemodialysis patients switched frome sevelamer to sucroferric oxyhydroxide: a 12-months follow-up","volume":"27","author":"Parameswaran","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0255","first-page":"616A","article-title":"Serum phosphorus and phosphate binder pills per day in peritoneal dialysis patients switched to sucroferric oxyhydroxide as part of routine care: a six-month follow-up","volume":"27","author":"Parameswaran","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.01.004_bib0260","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nephro.2015.11.005","article-title":"\u00c9volution de la prise en charge des troubles min\u00e9raux et osseux des patients h\u00e9modialys\u00e9s en France entre 2008\u00a0et 2012\u00a0: Observatoire national du m\u00e9tabolisme min\u00e9ral et osseux","volume":"12","author":"Pelletier","year":"2016","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2017.01.004_bib0265","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/ndt\/gft280","article-title":"Serum phosphorus levels and pill-burden are inversely associated with adherence in patients on hemodialysis","volume":"29","author":"Wang","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.01.004_bib0270","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hdi.12315","article-title":"Phosphate binder pill-burden, patient-reported non adherence, and mineral bone disorders markers: findings from the DOPPS","volume":"20","author":"Fissel","year":"2016","journal-title":"Hemodial Int"},{"key":"10.1016\/j.nephro.2017.01.004_bib0275","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.jrn.2016.01.009","article-title":"An update on phosphate binders: a dietititan's perspective","volume":"26","author":"Gutekunst","year":"2015","journal-title":"J Renal Nutr"},{"key":"10.1016\/j.nephro.2017.01.004_bib0140","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/ndt\/gfw278","article-title":"Screening for vascular calcification in incident dialysis patients is not systematically performed","volume":"31","author":"Mohun","year":"2016","journal-title":"Nephrol Dial Transplant"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.01.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:41:56Z","timestamp":1741192916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517300275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":28,"alternative-id":["S1769725517300275"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.01.004","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxyhydroxyde sucroferrique, un nouveau ch\u00e9lateur des phosphates \u00e0 base de fer. Quelle utilisation chez le patient dialys\u00e9\u00a0?","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Association Soci\u00e9t\u00e9 de n\u00e9phrologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}